Biological therapies targeting the inflammatory cytokine tumor necrosis factor-alpha (TNF-α) serve as robust treatment options for attenuating chronic inflammation in RA (Mitoma et al., 2018; Kerschbaumer et al., 2020). This evidence concerns the gene TNF and rheumatoid arthritis.